

60/028,740 (filed October 22, 1996), each of which is now abandoned.

In the Claims:

Kindly cancel claims 1-60 and 64-80, and add new claims 81-100 as follows.

Sub A 81. (New) A method of inducing apoptosis of a cell, said method comprising expressing in said cell a nucleic acid having 50% or greater nucleotide sequence identity to the nucleotide sequence of SEQ ID NO.: 3 and encoding a polypeptide capable of inducing apoptosis, said nucleic acid operably linked to a heterologous regulatory sequence for expression of said polypeptide, wherein expressing said nucleic acid in said cell induces apoptosis of said cell.

82. (New) The method of claim 81, wherein said nucleotide sequence identity is 75% or greater to the nucleotide sequence of SEQ ID NO.: 3.

83. (New) The method of claim 82, wherein said nucleotide sequence identity is 90% or greater to the nucleotide sequence of SEQ ID NO.: 3.

Sub B 84. (New) A method of inducing apoptosis of a cell, said method comprising expressing in said cell a nucleic acid capable of hybridizing at high stringency to the complement of the nucleic acid of SEQ ID NO.: 3 and encoding a polypeptide capable of inducing apoptosis, said nucleic acid operably linked to a heterologous regulatory

sequence for expression of said polypeptide, wherein expressing said nucleic acid in said cell induces apoptosis of said cell.

Sub C² 85. (New) The method of claim 81 or 84, wherein said regulatory sequence is capable of expressing said nucleic acid in a constitutive, inducible, or cell-type specific manner.

A² 86. (New) The method of claim 81 or 84, wherein said nucleic acid is in an adenoviral vector or a retroviral vector.

87. (New) The method of claim 81 or 84, wherein said cell is a cancer cell.

Sub B² 88. (New) A pharmaceutical composition comprising (i) a substantially purified nucleic acid capable of hybridizing at high stringency to the complement of the nucleic acid of SEQ ID NO.: 3 and encoding a polypeptide capable of inducing apoptosis, and (ii) a pharmaceutically acceptable carrier, wherein said nucleic acid is operably linked to a heterologous regulatory sequence for expression of said polypeptide in a mammalian cell.

89. (New) A pharmaceutical composition comprising (i) a nucleic acid having 50% or greater nucleotide sequence identity to the nucleotide sequence of SEQ ID NO.: 3 and encoding a polypeptide capable of inducing apoptosis, and (ii) a pharmaceutically

acceptable carrier, wherein said nucleic acid is operably linked to a heterologous
regulatory sequence for expression of said polypeptide in a mammalian cell.

90. (New) The composition of claim 89, wherein said nucleotide sequence
identity is 75% or greater to the nucleotide sequence of SEQ ID NO.: 3.

A 91. (New) The composition of claim 90, wherein said nucleotide sequence
identity is 90% or greater to the nucleotide sequence of SEQ ID NO.: 3.

Sub C 92. (New) The composition of claim 88 or 89, wherein said regulatory sequence
is capable of expressing said nucleic acid in a constitutive, inducible, or cell-type specific
manner.

93. (New) The composition of claim 88 or 89, wherein said nucleic acid is in an
adenoviral vector or a retroviral vector.

94. (New) The composition of claim 88 or 89, wherein said nucleic acid encodes
a polypeptide having a conservative *B* amino acid substitution relative to the amino acid
sequence of SEQ ID NO.: 4.

Sub B 95. (New) An expression vector comprising a nucleic acid capable of hybridizing

at high stringency to the complement of the nucleic acid of SEQ ID NO.: 3 and encoding a polypeptide capable of inducing apoptosis, wherein said nucleic acid is operably linked to a heterologous regulatory sequence for expression of said polypeptide in a mammalian cell.

A 2
96. (New) An expression vector comprising a nucleic acid having 50% or greater nucleotide sequence identity to the nucleotide sequence of SEQ ID NO.: 3 and encoding a polypeptide capable of inducing apoptosis, wherein said nucleic acid is operably linked to a heterologous regulatory sequence for expression of said polypeptide in a mammalian cell.

97. (New) The expression vector of claim 96, wherein said nucleotide sequence identity is 75% or greater to the nucleotide sequence of SEQ ID NO.: 3.

98. (New) The expression vector of claim 97, wherein said nucleotide sequence identity is 90% or greater to the nucleotide sequence of SEQ ID NO.: 3.

Sub C
99. (New) The expression vector of claim 95 or 96, wherein ~~said regulatory sequence is capable of expressing~~ said nucleic acid in a constitutive, inducible, or cell-type specific manner.